Id: acc3151
Group: 2sens
Protein: Chk1
Gene Symbol: CHEK1
Protein Id: O14757
Protein Name: CHK1_HUMAN
PTM: phosphorylation
Site: Ser317
Site Sequence: SEENVKYSSSQPEPRTGLSLW
Disease Category: Cancer
Disease: Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline: Hep3B
Disease Info:
Drug: HKH40A
Drug Info: "HKH40A is a drug with potential medical applications, although specific details about it are not provided."
Effect: modulate
Effect Info: "Inhibiting the activity of Cdc25C through Chk1/2 - mediated inhibitory phosphorylation leads to the phosphorylation of downstream Cdk1 and cell cycle G2/M arrest, thereby inducing cell apoptosis."
Note:
Score: 4.0
Pubmed(PMID): 19530246
Sentence Index:
Sentence:

Sequence & Structure:

MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGFSKHIQSNLDFSPVNSASSEENVKYSSSQPEPRTGLSLWDTSPSYIDKLVQGISFSQPTCPDHMLLNSQLLGTPGSSQNPWQRLVKRMTRFFTKLDADKSYQCLKETCEKLGYQWKKSCMNQVTISTTDRRNNKLIFKVNLLEMDDKILVDFRLSKGDGLEFKRHFLKIKGKLIDIVSSQKIWLPAT

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Terminated lymphoma ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Completed small cell lung carcinoma ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Terminated melanoma ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
CHEK1 RABUSERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Completed peritoneum cancer ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Completed fallopian tube cancer ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Unknown status kidney cancer ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Completed cancer ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Completed ovarian cancer ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Terminated ovarian cancer ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 2 Terminated breast cancer ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 2 Completed ovarian cancer ClinicalTrials
CHEK1 XL-844 Serine/threonine-protein kinase Chk1 inhibitor 1 Terminated chronic lymphocytic leukemia ClinicalTrials
CHEK1 SCH-900776 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed Hodgkins lymphoma ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed acute erythroleukemia ClinicalTrials
CHEK1 PREXASERTIB Serine/threonine-protein kinase Chk1 inhibitor 1 Completed myelodysplastic syndrome ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed myelodysplastic syndrome ClinicalTrials
ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed acute monocytic leukemia ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed acute myelomonocytic leukemia ClinicalTrials
CHEK1 SCH-900776 Serine/threonine-protein kinase Chk1 inhibitor 1 Terminated acute lymphoblastic leukemia ClinicalTrials
CHEK1 SCH-900776 Serine/threonine-protein kinase Chk1 inhibitor 1 Terminated acute myeloid leukemia ClinicalTrials
CHEK1 UCN-01 Serine/threonine-protein kinase Chk1 inhibitor 1 Completed acute promyelocytic leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CHEK1-Ser317
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 317 U Colorectal cancer Phosphorylation 32357935
S 317 U Multiple myeloma Phosphorylation 35190641

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: